Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia

被引：6
|
作者：
Tam, Constantine S. [1 ,8 ]
Trotman, Judith [2 ,3 ]
Opat, Stephen [4 ,5 ]
Stern, Jennifer C. [6 ]
Allewelt, Heather [6 ]
By, Kunthel [6 ]
Novotny, William [6 ]
Huang, Jane [6 ]
Tedeschi, Alessandra [7 ]
机构：
[1] Monash Univ, Alfred Hosp, Melbourne, Vic, Australia
[2] Concord Repatriat Gen Hosp, Concord, NSW, Australia
[3] Univ Sydney, Concord, NSW, Australia
[4] Monash Hlth, Clayton, Vic, Australia
[5] Monash Univ, Clayton, Vic, Australia
[6] BeiGene, San Mateo, CA USA
[7] ASST Grande Osped Metropolitano Niguarda, Milan, Italy
[8] Alfred Hosp, 55 Commercial Rd, Melbourne, Vic, Australia
来源：
BLOOD ADVANCES | 2023年 / 7卷 / 12期
关键词：
D O I：
10.1182/bloodadvances.2022008990
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2884 / 2887
页数：4
相关论文
共 50 条
  • [21] Moxetumomab Pasudotox Clinical experience in relapsed/refractory hairy cell leukemia
    Feurtado, Julie
    Kreitman, Robert J.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2019, 23 (03) : E52 - E59
  • [22] Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia
    Tadmor, Tamar
    Yurkovski, Ilana Levy
    LEUKEMIA & LYMPHOMA, 2024, 65 (05) : 684 - 687
  • [23] EFFICACY OF RITUXIMAB-THERAPY IN RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA
    Cheveresan, L.
    Cheveresan, M.
    Ionta, H.
    Nicola, D.
    Calamar, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 527 - 527
  • [24] Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia
    Tiacci, Enrico
    De Carolis, Luca
    Simonetti, Edoardo
    Capponi, Monia
    Ambrosetti, Achille
    Lucia, Eugenio
    Antolino, Agostino
    Pulsoni, Alessandro
    Ferrari, Samantha
    Zinzani, Pier L.
    Ascani, Stefano
    Perriello, Vincenzo M.
    Rigacci, Luigi
    Gaidano, Gianluca
    Della Seta, Roberta
    Frattarelli, Natalia
    Falcucci, Paolo
    Foa, Robin
    Visani, Giuseppe
    Zaja, Francesco
    Falini, Brunangelo
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (19): : 1810 - 1823
  • [25] Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia
    Tiacci, E.
    Park, J. H.
    De Carolis, L.
    Chung, S. S.
    Broccoli, A.
    Scott, S.
    Zaja, F.
    Devlin, S.
    Pulsoni, A.
    Chung, Y. R.
    Cimminiello, M.
    Kim, E.
    Rossi, D.
    Stone, R. M.
    Motta, G.
    Saven, A.
    Varettoni, M.
    Altman, J. K.
    Anastasia, A.
    Grever, M. R.
    Ambrosetti, A.
    Rai, K. R.
    Fraticelli, V.
    Lacouture, M. E.
    Carella, A. M.
    Levine, R. L.
    Leoni, P.
    Rambaldi, A.
    Falzetti, F.
    Ascani, S.
    Capponi, M.
    Martelli, M. P.
    Park, C. Y.
    Pileri, S. A.
    Rosen, N.
    Foa, R.
    Berger, M. F.
    Zinzani, P. L.
    Abdel-Wahab, O.
    Falini, B.
    Tallman, M. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (18): : 1733 - 1747
  • [26] Zanubrutinib: a new BTK inhibitor for treatment of relapsed/refractory mantle cell lymphoma
    Weaver, A. N.
    Jimeno, A.
    DRUGS OF TODAY, 2020, 56 (08) : 531 - 539
  • [27] Treatment of relapsed/refractory chronic lymphocytic leukemia with Zanubrutinib after progressing on other BTK inhibitors
    Nwankwo, Nkolika
    Reddy, Aswanth
    Kumar, Swarup
    Zafar, Maha
    LEUKEMIA RESEARCH REPORTS, 2024, 21
  • [28] Fludarabine and Rituximab (FR) Is a Safe and Effective Treatment Alternative for Relapsed or Refractory Hairy Cell Leukemia (HCL)
    Gerrie, Alina S.
    Zypchen, Leslie N.
    Connors, Joseph M.
    BLOOD, 2010, 116 (21) : 1019 - 1019
  • [29] How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors
    Falini, Brunangelo
    De Carolis, Luca
    Tiacci, Enrico
    BLOOD, 2022, 139 (15) : 2294 - 2305
  • [30] Dabrafenib Is a Safe and Effective Therapy in Relapsed/Refractory Classical Hairy Cell Leukemia
    Cross, Matthew J.
    Shah, Paras
    Heelan, Kara
    Dearden, Claire E.
    El-Sharkawi, Dima
    Iyengar, Sunil
    BLOOD, 2020, 136
12345